EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study

Do Young Kim, Chang-Ki Min, Hyeon-Seok Eom, Jongheon Jung, Kihyun Kim, Jae Hoon Lee, Kwai Han Yoo, Ji Yun Lee, Ja Min Byun, Sung-Hyun Kim, Ji Hyun Lee, Hee Jeong Cho und 10 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.06.006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Do Young Kim und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Biochemical Research Institution, Pusan National University Hospital, Pusan Nationa…. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Dexamethasone, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Pusan National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lenalidomide-based triplet regimens, specifically carfilzomib, lenalidomide, and dexamethasone (KRd) and ixazomib, lenalidomide, and dexamethasone (IRd), are recognized as effective treatments for relapsed/refractory multiple myeloma (RRMM). Since 2020, South Korea's National Health Insurance Service has covered these combinations, prompting a need for real-world comparisons of their efficacy and safety. METHODS: A retrospective analysis of 182 RRMM patients treated with KRd (112) or IRd (70) at 17 South Korean centers from May 2020 to April 2021 was conducted. RESULTS: Better outcomes for the KRd were expected according to previous randomized controlled trials (RCT). However, there was no significant difference in the overall response rate between the two groups (89.1 vs. 87.0%, P = .67). Responses above very good partial response tended to be higher in the KRd (70.9 vs. 58.0%, P = .075), although not statistically significant. In terms of treatment maintenance, the two groups had a 9.3-month difference in progression-free survival, but it was not statistically significant (19.1 vs. 28.4 months, P = .08). Overall survival was longer for IRd (31.6 months vs. not achieved, P = .02). Analysis revealed that the proper toxicity control and dose modification have influenced these results. Subgroup analysis found no difference in treatment outcome between the two treatments in high-risk patients. CONCLUSIONS: Comparing the two treatments in the real-world revealed inconsistent outcomes from the predictions based on RCTs. The KRd showed an advantage in the depth of response, while the IRd showed an advantage in the duration of the response. The findings will be helpful in choosing the best strategies of treatment for patients with RRMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsGlycineNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesBoron CompoundsOligopeptidesAdultAged, 80 and overRepublic of Korea

Stichwörter der Autor:innen

EfficacyPlasmacytomaReal world evidenceSafetySalvage Treatment

Substanzen

LenalidomideDexamethasoneixazomibcarfilzomibGlycineBoron CompoundsOligopeptides

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Biochemical Research Institution, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.
  • Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Division of Hematology, Gachon University Medical College, Gachon University Gil Medical Center, Incheon, Republic of Korea.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.

Förderung

  • Pusan National University

Zitieren

APA

Kim, D. Y., Min, C. K., Eom, H. S., Jung, J., Kim, K., Lee, J. H., Yoo, K. H., Lee, J. Y., Byun, J. M., Kim, S. H., Lee, J. H., Cho, H. J., Lee, S. M., Do, Y. R., Park, S., Lee, J., Lee, S. S., Kang, H. J., Park, Y. H., …, & Of The Korean Multiple Myeloma Working Party (2025). Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.06.006

Vancouver

Kim DY, Min CK, Eom HS, Jung J, Kim K, Lee JH, et al. Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.06.006

BibTeX
@article{Kim2025,
  author = {Kim, Do Young and Min, Chang-Ki and Eom, Hyeon-Seok and Jung, Jongheon and Kim, Kihyun and Lee, Jae Hoon and Yoo, Kwai Han and Lee, Ji Yun and Byun, Ja Min and Kim, Sung-Hyun and Lee, Ji Hyun and Cho, Hee Jeong and Lee, Sang Min and Do, Young Rok and Park, Sungwoo and Lee, Junglim and Lee, Seung-Shin and Kang, Hye Jin and Park, Young Hoon and Lim, Sung-Nam and Shin, Ho-Jin and Of The Korean Multiple Myeloma Working Party, Of The Korean Multiple Myeloma Working Party},
  title = {Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.06.006}
}
Kostenlos starten →